The association of trastuzumab with atrial fibrillation and heart failure in breast cancer patients in routine clinical practice: a population-based propensity score matching and competing risk model analysis

PURPOSE: Trastuzumab, a potent anti-human epidermal growth factor receptor 2 (HER2) monoclonal antibody, is conditionally reimbursed by the Taiwan National Health Insurance (NHI) for HER2-positive breast cancer (BC). Trastuzumab-induced cardiotoxicity studies have well characterized heart failure (H...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Wen-Chi, Huang, Chi-Cheng, Tsai, Yi-Fang, Lin, Yen-Shu, Feng, Chin-Jung, Chen, Yen-Jen, Lai, Jiun-I., Chao, Ta-Chung, Liu, Chun-Yu, Tseng, Ling-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Epidemiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883308/
https://www.ncbi.nlm.nih.gov/pubmed/36586037
http://dx.doi.org/10.1007/s10549-022-06753-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883308/
https://www.ncbi.nlm.nih.gov/pubmed/36586037
http://dx.doi.org/10.1007/s10549-022-06753-7

Ejemplares similares